NASDAQ:UTHR - United Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$100.34 -0.31 (-0.31 %)
(As of 04/19/2019 04:00 PM ET)
Previous Close$100.65
Today's Range$98.77 - $102.40
52-Week Range$98.77 - $130.00
Volume520,843 shs
Average Volume375,485 shs
Market Capitalization$4.39 billion
P/E Ratio7.49
Dividend YieldN/A
Beta1.1
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. United Therapeutics Corporation has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin in the United States, the United Kingdom, Canada, France, Germany, Italy, and Japan; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop SM04646, a phase I development-stage Wnt pathway inhibitor for treating idiopathic pulmonary fibrosis. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$13.3254 per share
Book Value$63.98 per share

Profitability

Net Income$589.20 million

Miscellaneous

Employees860
Market Cap$4.39 billion
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How will United Therapeutics' stock buyback program work?

United Therapeutics announced that its Board of Directors has authorized a share repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase $250,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 4.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its stock is undervalued.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) announced its quarterly earnings results on Wednesday, February, 27th. The biotechnology company reported $1.48 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $2.20 by $0.72. The biotechnology company earned $381.40 million during the quarter, compared to analysts' expectations of $355.81 million. United Therapeutics had a net margin of 36.20% and a return on equity of 22.63%. The company's revenue for the quarter was down 17.9% on a year-over-year basis. During the same period in the previous year, the company posted $3.89 earnings per share. View United Therapeutics' Earnings History.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for United Therapeutics.

What price target have analysts set for UTHR?

9 Wall Street analysts have issued twelve-month price objectives for United Therapeutics' shares. Their forecasts range from $95.00 to $269.00. On average, they anticipate United Therapeutics' share price to reach $133.8750 in the next twelve months. This suggests a possible upside of 33.4% from the stock's current price. View Analyst Price Targets for United Therapeutics.

What is the consensus analysts' recommendation for United Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

What are Wall Street analysts saying about United Therapeutics stock?

Here are some recent quotes from research analysts about United Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Our price target of $95/share is based on an equally weighted composite of (a) $98/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $5.78 discounted back to and (b) an NPV of $92/share, discount rate 12.5%, growth rate -2%." (11/1/2018)
  • 2. According to Zacks Investment Research, "United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. The acquisition of SteadyMed added its drug device pipeline product Trevyent to its portfolio, which could have posed competition to Implantable System for Remodulin (ISR) which was approved recently in July with a launch scheduled for 2019. However, competition in the PAH market is increasing. Also two of its biggest products - Remodulin and Adcirca – are expected to face generic competition this year. United Therapeutics’ shares have also underperformed the industry so far this year." (10/22/2018)

Has United Therapeutics been receiving favorable news coverage?

Headlines about UTHR stock have been trending positive on Saturday, according to InfoTrie. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. United Therapeutics earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near future.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), General Electric (GE), Nektar Therapeutics (NKTR), NVIDIA (NVDA), Skyworks Solutions (SWKS), Allergan (AGN) and Alexion Pharmaceuticals (ALXN).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 64)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 47)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 51)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Greylin Investment Mangement Inc. (0.27%), Denali Advisors LLC (0.16%), Denali Advisors LLC (0.15%), Retirement Systems of Alabama (0.13%), DNB Asset Management AS (0.06%) and Nisa Investment Advisors LLC (0.05%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Denali Advisors LLC, Denali Advisors LLC, Greylin Investment Mangement Inc., Meeder Asset Management Inc. and Wedbush Securities Inc.. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

Which major investors are buying United Therapeutics stock?

UTHR stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, State of Alaska Department of Revenue, Virtu Financial LLC, Nisa Investment Advisors LLC, Eqis Capital Management Inc., Unison Advisors LLC, First Citizens Bank & Trust Co. and First Hawaiian Bank. View Insider Buying and Selling for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $100.34.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $4.39 billion and generates $1.63 billion in revenue each year. The biotechnology company earns $589.20 million in net income (profit) each year or $13.39 on an earnings per share basis. United Therapeutics employs 860 workers across the globe.

What is United Therapeutics' official website?

The official website for United Therapeutics is http://www.unither.com.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  405 (Vote Outperform)
Underperform Votes:  544 (Vote Underperform)
Total Votes:  949
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/20/2019 by MarketBeat.com Staff

Featured Article: What is the LIBOR?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel